Earnings Feed
Start Free
Allogene Therapeutics, Inc.·4

Feb 4, 5:04 PM ET

Belldegrun Arie 4

4 · Allogene Therapeutics, Inc. · Filed Feb 4, 2026

Research Summary

AI-generated summary of this filing

Updated

Allogene (ALLO) Director Arie Belldegrun Receives Equity Awards

What Happened Arie Belldegrun, a director of Allogene Therapeutics (ALLO), received two equity awards on February 2, 2026 totaling 1,192,946 derivative shares: 929,913 and 263,033 shares respectively. Both awards were reported as acquisitions at $0.00 per share (i.e., granted awards/derivatives rather than open-market purchases). One award is documented as Restricted Stock Units (RSUs) that vest in four equal annual installments; the other award carries a vesting schedule of 25% after one year (Feb 2, 2027) with the remainder vesting in 36 equal monthly installments.

Key Details

  • Transaction date: February 2, 2026; Filing date: February 4, 2026 (appears timely).
  • Awards: 929,913 derivative shares and 263,033 derivative shares; total 1,192,946 shares; price reported $0.00 (grants).
  • Vesting: RSUs vest in 4 equal annual installments starting Feb 2, 2026 (footnote F6). The other award vests 25% on Feb 2, 2027, then monthly over 36 months (footnote F5).
  • Shares owned after transaction: not specified in the provided excerpt of the filing.
  • Ownership notes: Some shares are held via trusts and Vida Ventures entities; the filer disclaims beneficial ownership of certain Vida-held shares except for any pecuniary interest (footnotes F1–F4).
  • Transaction type: Award/Grant (code A); derivative securities (not an immediate cash purchase or sale).

Context

  • Grants at $0.00 are standard equity compensation and do not represent an open-market buy or sell. Vesting is service-based, so the awards only convert to actual shares as they vest.
  • RSUs typically convert to one share per unit at vesting; the other award’s vest schedule resembles a time-based option/award. These awards do not by themselves indicate buying/selling sentiment but reflect compensation/retention.
  • The reporting person has connections to entities (Vida Ventures and family trusts) referenced in the filing; some holdings are held indirectly and may be disclaimed for beneficial ownership purposes.

Insider Transaction Report

Form 4
Period: 2026-02-02
Allogene Therapeutics, Inc.ALLO
Belldegrun Arie
Director
Transactions
  • Award

    Stock Option (Right to buy)

    [F5]
    2026-02-02+929,913→ 929,913 total
    Exercise: $1.87Exp: 2036-02-02→ Common Stock (929,913 underlying)
  • Award

    Restricted Stock Unit

    [F6]
    2026-02-02+263,033→ 263,033 total
    → Common Stock (263,033 underlying)
Holdings

  • Common Stock

    [F1]
    (indirect: See footnote)
    4,710,120

  • Common Stock

    [F2]
    (indirect: See footnote)
    1,798,163

  • Common Stock

    [F3]
    (indirect: See footnote)
    1,724,137

  • Common Stock

    [F4]
    (indirect: See footnote)
    539,867

  • Common Stock

    2,236,816
Footnotes (6)
  • [F1]The securities are held in the name of Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary
  • [F2]The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. There porting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  • [F3]The securities are held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. Vida Ventures GP III, LLC is the manager of Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person is a Senior Managing Director of Vida Ventures GP III, LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  • [F4]The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.
  • [F5]25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
  • [F6]Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period from February 2, 2026, subject to continued service through the vesting date.
Signature
/s/Earl Douglas, Attorney-in-Fact|2026-02-04

Documents

1 file
  • 4
    wk-form4_1770242650.xmlPrimary

    FORM 4